Piers Patten, BSc, MBChB, PhD

Clinical Senior Lecturer, Consultant Haematologist
King's College London, United Kingdom

N/A

Poster(s):

• 1210 - Imaging mass cytometry reveals distinct cellular architectures in proliferative and non-proliferative regions of the chronic lymphocytic leukaemia lymph node tumour microenvironment

• 1216 - BIOLOGICAL FEATURES of B-CLL AND RESIDUAL IMMUNITY AT TREATMENT INITIATION DETERMINE IMMUNITY ON BTKI THERAPY.

• 1224 - A fraction of lymph node CLL B cells exhibits high expression of T-bet

• 1415 - Health-related quality of life in patients with previously untreated chronic lymphocytic leukaemia treated with ibrutinib and rituximab or fludarabine, cyclophosphamide and rituximab: patient-reported outcomes from the multicentre, open-label, randomised, phase 3 FLAIR trial

• 1433 - Ibrutinib plus venetoclax with measurable residual disease-guided duration of treatment is superior to both ibrutinib monotherapy and fludarabine-cyclophosphamide-rituximab for previously untreated chronic lymphocytic leukaemia: Report of the Phase III UK NCRI FLAIR study.

• 1701 - Development and evaluation of a selection-algorithm optimised ensemble model for predicting infection risk in CLL using structured and unstructured electronic patient record data

• 1711 - A 3 week pause versus continued BTKi during vaccination (IMPROVE): a randomised, open-label, superiority trial.

• 1713 - An assessment of NK and T cell functional immunity in response to vaccination whilst taking acalabrutinib or ibrutinib monotherapy.

• 1804 - BRD4 maintains the surface phenotype of Chronic Lymphocytic Leukemia cells